Guangzhou Baiyunshan Pharmaceutical Holdings Company (874) Q1 2026 earnings summary

Executive summary

• Operating income for Q1 2026 reached RMB 23.28 billion, up 3.58% year-over-year.

• Net profit attributable to shareholders was RMB 1.78 billion, down 2.06% compared to Q1 2025.

• Total assets increased by 6.21% to RMB 89.76 billion as of March 31, 2026.

Financial highlights

• Operating profit for Q1 2026 was RMB 2.20 billion, a slight decrease from RMB 2.23 billion in Q1 2025.

• Basic and diluted EPS were both RMB 1.097, down from RMB 1.120 year-over-year.

• Net cash flow from operating activities improved significantly to negative RMB 2.22 billion from negative RMB 3.90 billion in Q1 2025.

• Total equity attributable to shareholders rose 4.69% to RMB 39.56 billion.

Outlook and guidance

• Improved cash collection from enterprises contributed to better operating cash flow.